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In Brief
Tumors can act over extended distances
to stimulate tumor-promoting immune
responses, but the long-range signals
involved remain poorly understood. Pucci
et al. now suggest that platelet factor 4
(PF4) can stimulate bone marrow
megakaryopoiesis and lung cancer
progression.
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Co-option of host components by solid tumors facil-
itates cancer progression and can occur in both local
tumor microenvironments and remote locations.
At present, the signals involved in long-distance
communication remain insufficiently understood.
Here, we identify platelet factor 4 (PF4, CXCL4) as
an endocrine factor whose overexpression in tumors
correlates with decreased overall patient survival.
Furthermore, engineered PF4 over-production in a
Kras-driven lung adenocarcinoma genetic mouse
model expanded megakaryopoiesis in bone marrow,
augmented platelet accumulation in lungs, and
accelerated de novo adenocarcinogenesis. Addi-
tionally, anti-platelet treatment controlled mouse
lung cancer progression, further suggesting that
platelets can modulate the tumor microenvironment
to accelerate tumor outgrowth. These findings sup-
port PF4 as a cancer-enhancing endocrine signal
that controls discrete aspects of bonemarrow hema-
topoiesis and tumor microenvironment and that
should be considered as a molecular target in anti-
cancer therapy.
INTRODUCTION
Diverse tumor-associated host cells, including endothelial cells,
fibroblasts, and hematopoietic cells, are often locally co-opted
by tumors to enable tumorigenesis or sustain tumor outgrowth
(Hanahan and Coussens, 2012; Engblom et al., 2016). The study
of the cellular and molecular mechanisms underlying the tumor
microenvironment has generated not only new anticancer treat-
ments, such as immuno- and antiangiogenic therapies, but also1764 Cell Reports 17, 1764–1772, November 8, 2016 ª 2016 The Au
This is an open access article under the CC BY-NC-ND license (http://a new field of fundamental investigation centered on the
ontogeny of tumor-infiltrating host cells (McAllister and Wein-
berg, 2014; Pittet et al., 2014). This research has discovered
that growing tumors can continuously recruit new hematopoietic
cells from the circulation by releasing signals that amplify the
production of hematopoietic progenitors in remote hematopoiet-
ic organs. Long-range tumor-associated signals include osteo-
pontin, a tumor-secreted endocrine factor that activates bone
marrow cells (McAllister et al., 2008); G-CSF, a tumor-derived
factor that promotes bone marrow myelopoiesis (Casbon
et al., 2015); and Angiotensin-II, a peptide hormone that
instigates extramedullary monocytopoiesis (Cortez-Retamozo
et al., 2013). However, while local immune-neoplastic interac-
tions in the microenvironment are well studied, several aspects
of systemically activated tumor-associated immune compo-
nents remain unclear.
Here we aimed to identify new candidate long-range commu-
nication signals involved in lung adenocarcinoma. We focused
on this disease because it is the leading cause of cancer death
(Torre et al., 2016) and because newly available high-throughput
datasets allowed us to interrogate this disease in both patients
(Nguyen et al., 2009) and genetic mouse models that closely
recapitulate the human disease (Taguchi et al., 2011). Initially,
we developed a screening strategy that considered the following
three defining properties of tumor-associated endocrine factors:
(1) their expression in tumors should be altered in both murine
and human lung adenocarcinomas, (2) their changed expression
should be associated with differences in patient survival, and (3)
their plasma concentration should bemodified in lung adenocar-
cinoma-bearing mice. Interrogating these phenotypes in both
humans and mice enabled us to identify circulating factors that
may be relevant to human disease and that can be manipulated
genetically to allow murine analyses of mechanisms and
causality.
This strategy identified several factors and, of these, platelet
factor 4 (PF4) seemed the most prominent in lung cancer. Wethors.
creativecommons.org/licenses/by-nc-nd/4.0/).
next performed deeper biological studies to identify whether
systemically overexpressed PF4 instigates hematopoietic cell
production away from the tumor stroma, instructs differentiation
of defined hematopoietic cell types, and alters the tumor micro-
environment and tumorigenesis. To this end, we compared lung
adenocarcinoma genetic mouse models that expressed Pf4 at
either low or high levels, and we genetically induced systemic
PF4 production in mice that otherwise expressed this factor at
low levels. In doing so, we found PF4 to be responsible for stim-
ulating discrete tumor-induced changes, namely megakaryo-
cytic expansion in bone marrow and platelet accumulation
at the tumor site. Furthermore, systemic PF4 production
substantially accelerated Kras-driven tumorigenesis, a result
that supports this factor as a tumor-promoting signal that con-
nects lung tumors to distinct bone-marrow hematopoietic
components.
RESULTS
Identification of Candidate Long-Range Factors
Associated with Altered Patient Survival
To identify previously unknown long-range communication sig-
nals involved in lung adenocarcinoma, we screened in silico
candidate long-range factors in Kras lung adenocarcinoma-
bearingmice (Taguchi et al., 2011) and lung adenocarcinoma pa-
tients (Nguyen et al., 2009) (Figure 1A). By considering plasma
proteins with significantly varied expression (p < 0.05) in tumor-
bearingmice, when compared to tumor-free littermates (Taguchi
et al., 2011), we short-listed 60 candidate factors, of which 33
were over-abundant and 27 were under-abundant (Figure S1A).
To assess these 60 factors in lung adenocarcinoma patients,
we mined both tumor transcriptome profiles (at time of diag-
nosis) and survival data from 225 patients (Nguyen et al.,
2009). Specifically, we compared the overall patient survival
with highest (top 20%) and lowest (bottom 20%) mRNA expres-
sion levels for each candidate factor. Of the 33 over-abundant
factors noted above, six were associated with altered patient
survival (p < 0.05 after Bonferroni correction): overexpression
of three of them (Pf4, Agt, and Ppia) correlated with decreased
patient survival, while overexpression of the remaining three
(Npc2,Sftpb, andSlit2) correlatedwith increased patient survival
(Figure 1B). Of the 27 under-abundant factors noted above, five
were associated with altered patient survival: under-expression
of four of them (Prg4, Rgn, Sepp1, and Thumpd1) correlated
with decreased patient survival while under-expression of
Wdr62 correlated with increased patient survival (Figure 1C).
Overall, this screening identified four candidate harmful factors
(Pf4, Agt, Ppia, andWdr62) and seven candidate protective fac-
tors (Npc2, Prg4, Rgn, Sepp1, Sftpb, Slit2, and Thumpd1) in lung
adenocarcinoma. Thus, 11 of the initial 60 candidates were
associated with altered overall patient survival. For comparison,
when assessing 60 randomly selected genes, we found that only
2.6 ± 0.2 (mean ± SEM, n = 60 iterations) of them were associ-
ated with differences in patient survival. Consequently, seeding
our screening with cancer-associated endocrine factors signifi-
cantly increased the chance that such candidates also were
associated with survival changes (11 compared to 2.6 ± 0.2;
p < 0.0001).To further test the harmful and protective candidate factors
identified above, we evaluated whether their transcript levels
were altered at the tumor site in lung adenocarcinoma models
driven by either oncogenic Kras only (KrasG12D, hereafter
referred to as K) or oncogenic Kras and p53 deletion
(KrasG12D;p53fl/fl, hereafter referred to as KP). We used these
two genetic models because they both carry mutations
frequently found in human lung adenocarcinoma (KRAS and
TP53 are mutated in 25% and 50% of patients, respectively)
but may co-opt the host immune response differently and pro-
duce different protective and harmful factors. Cre-expressing
adenoviruses were introduced intranasally into K or KP mice to
enable Cre delivery to lung epithelial cells and allow tumors to
arise in the tissue (DuPage et al., 2009). We assayed intratumoral
mRNA expression levels when tumor burden was similar in both
models (Figure S1B), i.e., at week 20 for K mice and at week 11
for KPmice. Our assay also included tumor-free lungs as control
tissue. Two of seven harmful candidate genes (Pf4 and Agt) and
two of four protective candidate genes (Npc2 and Sftpb) were
significantly overexpressed in KP tumors; Sftpb also was over-
expressed in K tumors (Figure 1D). The candidate protective
factor Prg4 was under-expressed in K mice (Figure 1E).
PF4 as a Candidate Lung Adenocarcinoma-Promoting
Factor
Of the harmful candidate factors identified above, we sought to
further interrogate PF4 because it was most highly (30-fold)
overexpressed in KP nodules when compared to K nodules
and tumor-free lungs (Figure 1D). Also, PF4 levels in circulation
and within tumors have been associated with increased tumor
growth (Poruk et al., 2010), but whether PF4 causally affects tu-
mor development has remained unknown. Additionally, defining
whether and how PF4 impacts distant organs and/or plays a role
in tumor-host communication required study. Our initial data
indicated a strong association between PF4 overexpression
and tumor development based on increased circulating PF4
plasma levels in Kras-driven lung tumor models (Figure S1A)
and decreased overall survival in patients with high PF4 expres-
sion in tumor nodules (Figure 1B). The latter finding was
confirmed using independent lung adenocarcinoma datasets
from 665 patients (Shedden et al., 2008) (Figure S1C). Also, sta-
tistical analysis of demographic data from the two cohorts of pa-
tients identified based on PF4 expression levels in tumors (i.e.,
PF4HI and PF4LO patients) did not identify a bias that could
explain the underlying difference in survival (Figure S1D).
In subsequent experiments, we genetically augmented sys-
temic PF4 production in K mice, which were otherwise poor
Pf4 expressers (Figure 1D), and we asked whether this change
was sufficient to induce discrete alterations in hematopoietic tis-
sues and the tumor microenvironment that could foster tumor
progression. To increase systemic PF4 levels in K mice, we
created a lentiviral vector (PF4-LV) containing the native murine
Pf4 coding sequence under the strong constitutive promoter/
enhancer hEF1a (Figure 2A), and we injected concentrated
PF4-LV preparations intravenously (i.v.) to transduce liver cells
in vivo. An LV lacking the Pf4 expression cassette was used as
a control (Ctrl-LV) (Figure S2A). We excluded marker genes in
both vectors to avoid immune clearance of transduced cellsCell Reports 17, 1764–1772, November 8, 2016 1765
Figure 1. PF4 Is a Candidate Long-Range Factor Associated with Altered Survival in Lung Adenocarcinoma
(A) Workflow to identify candidate long-range endocrine signals involved in lung adenocarcinoma progression. The in silico screening employed a mouse
proteomic dataset that cross-referenced a list of 60 candidate factors with patient microarray data to short-list 11 factors associated with altered patient survival
(left panels). Leads were tested experimentally in K and KP mice (middle panels), and one factor was selected for further functional studies (right panel).
(B) Identification of six factors over-abundant in plasma of lung adenocarcinoma-bearing mice as compared to tumor-free mice (top row) and whose over-
expression was associated with decreased (Pf4, Agt, and Ppia) or increased (Npc2, Sftpb, and Slit) survival in lung adenocarcinoma patients (bottom row).
Kaplan-Meier survival curves are shown for patients with highest (top 20%, n = 45) and lowest (bottom 20%, n = 45) mRNA expression levels for each factor.
(C) Identification of five factors under-abundant in plasma of lung adenocarcinoma-bearing mice as compared to tumor-free mice (top row) and whose over-
expression was associated with increased (Prg4, Rgn, Sepp1, and Thumpd1) or decreased (Wdr62) survival in lung adenocarcinoma patients (bottom row).
Kaplan-Meier survival curves are shown for patients with highest (top 20%, n = 45) and lowest (bottom 20%, n = 45) mRNA expression levels for each factor.
(D and E) mRNA levels in K and KPmouse lungs (as compared to tumor-free lungs) when tumor burden was similar in both models, i.e., at week 20 for K mice and
at week 11 for KP mice. Candidate factors from (B) and (C) are shown in (D) and (E), respectively (n = 3–8).
Results are expressed as mean ± SEM (*p < 0.05, **p < 0.01, and ****p < 0.0001). Abbreviations are as follows: K, KrasG12D; KP, KrasG12D;p53fl/fl; ns, not sig-
nificant; NSCLC, non-small-cell lung cancer. See also Figure S1.
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Figure 2. Systemic PF4 Production Selectively Expands the Bone Marrow Megakaryocyte Lineage
(A) Schematics of PF4-LV features. Mouse native Pf4 coding gene is constitutively expressed under a strong promoter, without any marker gene or tag that may
elicit an immune rejection of PF4-overexpressing cells.
(B) ELISA for PF4 on total liver cell culture supernatants from tumor-free (ø), Ctrl-LV-, and PF4-LV-treated K mice is shown.
(C) Illustrated experimental design. K mice were dosed intranasally with adenoviral vectors expressing Cre to activate oncogenic Kras. After 9 weeks, they
received PF4-LV (or Ctrl-LV) i.v. to start systemic PF4 overexpression; at week 17, mice were euthanized and analyzed.
(D) Flow cytometry-based analysis of bone marrow (BM) and spleen total viable cells from mice treated as in (C).
(E and F) Flow cytometry-based analysis of BM hematopoietic stem/progenitor cells (E) and selected progeny (F) frommice treated as in (C). KPmice were added
as controls since they natively overexpress PF4 (see Figure 1D).
(G) Cartoon depicts hematopoietic hierarchy and illustrates PF4-induced expansion of the megakaryopoietic lineage (in light blue).
Results are expressed as mean ± SEM (*p < 0.05, **p < 0.01, and ****p < 0.0001). Abbreviations are as follows: BM, bone marrow; CLP, common lymphoid
progenitor; CMP, common myeloid progenitor; Ctrl, control; EP, erythroid progenitor; GMP, granulocyte-macrophage progenitor; K, KrasG12D; KP,
KrasG12D;p53fl/fl; LT-HSCs, long-term hematopoietic stem cell; LV, lentivector; MDP, monocyte-dendritic cell progenitor; MK, megakaryocyte; MKP, mega-
karyocyte progenitor; MPP, multipotent progenitor; ns, not significant; RBC, red blood cell. See also Figure S2.
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(Brown et al., 2006). Liver cells obtained from PF4-LV-treated K
mice on week 8 post-LV injection secreted 1.3–1.5 times more
PF4 than those from either Ctrl-LV-treated K mice or tumor-free
control mice (Figure 2B). Furthermore, vector copy number in
liver cells remained detectable at week 8, suggesting that PF4-
producing cells were not cleared by the host immune system
(Figure S2B). These results indicated the possibility of modu-
lating the expression of a candidate systemic factor and testing
its impact on the host and tumor progression in mice.
Systemic PF4 Selectively Expands the Bone Marrow
Megakaryocyte Lineage
To assess PF4’s impact on host responses to lung cancer, we
induced de novo carcinogenesis in Kmice by intranasally admin-
istering Cre-expressing adenoviral vectors. Next, we instigated
systemic PF4 production at week 9 by delivering PF4-LV i.v.,
and then we analyzed hematopoietic cells in various tissues at
week 17 (Figure 2C). PF4-LV-treated K mice showed signifi-
cantly increased cellularity in the bone marrow, but not in the
spleen, when compared to Ctrl-LV-treated K mice (Figure 2D);
this distinguishes PF4 from AGT, which instead selectively in-
creases splenic cellularity (Cortez-Retamozo et al., 2013).
We then examined PF4’s impact on bone marrow hematopoi-
etic stem and progenitor cells and more mature immune cell
lineages. We compared PF4-LV-treated and Ctrl-LV-treated K
mice as mentioned above, as well as unmanipulated KP mice
since their tumors naturally overexpressed Pf4 (Figure 1D). In
comparison to Ctrl-LV-treated K mice, KP mice contained
more hematopoietic stem and progenitor cell populations
(Figure 2E; Figure S2C), including long-term hematopoietic
stem cells (LT-HSCs), multipotent progenitors (MPPs), common
lymphoid progenitors (CLPs), granulocyte/macrophage progen-
itors (GMPs), macrophage/dendritic cell progenitors (MDPs),
and megakaryocyte progenitors (MKPs). KP mice also showed
more mature bone marrow immune cell lineages, including
monocytes, neutrophils, and megakaryocytes (Figure 2F).
By contrast, PF4-LV treatment in K mice instigated a narrower
blood lineage alteration. Among hematopoietic stem and
progenitor cell populations, PF4-LV-treated K mice selectively
expanded common myeloid progenitors (CMPs) and MKPs
when compared to Ctrl-LV-treated K mice, while LT-HSCs,
MPPs, CLPs, GMPs, and MDPs remained detectably un-
changed (Figure 2E). Additionally, PF4-LV-infected K mice
showed increased bone marrow megakaryocytes, but neither
monocytes nor neutrophils (Figure 2F). As expected, PF4-LV-
treated K mice did not have more hematopoietic stem and pro-
genitor cells in the spleen (Figure S2D). These findings indicate
that systemic PF4 overexpression specifically mediates a bone
marrow megakaryopoietic response (CMPs/MKPs/mega-
karyocytes; Figure 2G).
PF4 Increases Platelet Accumulation in Tumor-Bearing
Lungs
Based on PF4’s impact on bone marrow megakaryopoiesis, we
reasoned that this factor may influence the tumor microenviron-
ment by increasing platelet accumulation. Initially, we validated a
monoclonal antibody (mAb) against mouse platelet glycoprotein
Ib alpha chain CD42b (Figures S3A and S3B). We then stained1768 Cell Reports 17, 1764–1772, November 8, 2016lung histology sections from PF4-LV- and Ctrl-LV-treated K
mice as well as KP mice (Figure 3A), double-blind quantified by
mCD42b signal (Figure 3B). This analysis identified increased
CD42b+ platelet cluster accumulation in the lungs of PF4-LV-
treated mice. As expected, KP tumor-bearing lungs showed
high CD42b+ platelet cluster accumulation (Figures 3A and 3B).
Additional ex vivo flow cytometry-based analysis revealed that
the abundance of other immune cell types remained unchanged
in the lungs of PF4-LV-treated K mice as compared to their Ctrl-
LV-treated counterparts (Figure 3C; Figure S3C). These data
confirm that PF4 selectively amplified the megakaryocyte line-
age in the bone marrow without affecting the lymphoid cell and
phagocyte lineages. The selective change in platelet accumula-
tion at the tumor site indicates PF4 drives this phenotype directly
(as opposed to PF4 affecting other cells that would then recruit
platelets to the tumor stroma).
To test whether the results detailed above had clinical corre-
lates, we assessed platelet accumulation in lung adenocarci-
noma patients. We used an anti-human CD42b mAb that, we
confirmed, labels CD45 platelets and does not cross-react
with other CD45+ white blood cells (Figure S3D). We then as-
sessed tumor infiltration by platelets in 29 tumor biopsy sec-
tions from non-small-cell lung cancer (NSCLC) patients geno-
typed for KRAS and TP53 mutations. KRAS/TP53-mutated
tumors showed increased platelet infiltration when compared
to KRAS- and TP53-mutated tumors and tumor-free tissue (Fig-
ures 3D and 3E; Figure S3E). Although the number of patients
carrying both mutations was limited, these findings indicate
that platelets efficiently accumulate in at least a fraction of hu-
man lung tumors and that the K and KP mouse models are rele-
vant for studying tumors that share features with their human
counterparts.
Platelets andCirculating PF4PromoteKras-Driven Lung
Adenocarcinogenesis
Treatment of KP tumor-bearing mice with clopidogrel, an inhib-
itor of platelet aggregation and activation (Quinn and Fitzgerald,
1999), reduced cancer growth, as characterized by decreased
lung weight (Figure 4A) and lung tumor burden (Figures 4B and
4C). Clopidogrel-treated mice, but not the PBS-treated controls,
also maintained their overall body weight (Figure S4A) during the
course of the experiment. These results indicate that platelets
enhance KP tumor growth.
Conversely, we asked whether systemically increased PF4
production accelerates de novo lung tumor progression in K
mice. Indeed, we found increased lung weights in PF4-LV-
treated K mice as compared to their Ctrl-LV-treated counter-
parts (Figure 4D). We also generated whole-lung histological
sections to evaluate whether PF4-LV-treated K mice’s heavier
lungswere due to higher tumor burden (Figure 4E). Quantified tu-
mor area in these sections confirmed elevated tumor burden in
PF4-LV-treated compared to control mice (Figure 4F). We also
noted more tumor foci in PF4-LV mice than in their Ctrl-LV coun-
terparts (Figure 4G). Together, these results provide in vivo evi-
dence that increased systemic PF4 levels accelerate K tumor
progression. PF4 did not accelerate K tumor growth in isolation
in vitro (Figure S4B), further indicating that increased PF4 pro-
duction fosters tumor growth by acting on host cell components.
Figure 3. Systemic PF4 Production Amplifies Platelet Accumulation at the Tumor Site
(A) Immunohistochemistry staining for mCD42b (dark brown) on lung sections from Kmice treated with either Ctrl- or PF4-LV and from KPmice. Left panels show
mCD42b signal (split brown channels), whereas right panels show original DAB staining (brown) with hematoxylin counterstain (blue). Scale bars represent
100 mm.
(B) Quantification of percentage mCD42b+ areas per field of views, based on immunohistochemistry staining in (A), is shown.
(C) Flow cytometry-based quantification of various immune cell types in the lungs of K mice treated with either Ctrl- or PF4-LV is shown.
(D) Immunohistochemistry staining for hCD42b (red) on lung cancer patient tissue microarrays. Representative biopsies of KRAS-mutated (left), TP53-mutated
(center), and both KRAS- and TP53-mutated tumors (right) are shown. Scale bars represent 0.5 mm.
(E) Quantification of hCD42b+ clusters per square centimeter, based on immunohistochemistry staining in (D), is shown.
Results are expressed as mean ± SEM (**p < 0.01 and ***p < 0.001). Abbreviations are as follows: cDC, classical dendritic cell; ctrl, control; K, KrasG12D; KP,
KrasG12D;p53fl/fl; LV, lentivector; mono., monocyte; mut., mutant; NK, natural killer; ns, not significant; pDC, plasmacytoid dendritic cell; TAM, tumor-associated
macrophage; TAN, tumor-associated neutrophil. See also Figure S3.DISCUSSION
By cross-analyzing selected datasets from human and mouse
lung adenocarcinomas, we identified candidate factors that
may act as endocrine signals in tumor-host communication.
Furthermore, by manipulating systemic PF4 production, we vali-
dated this factor as a key constituent that alters discrete compo-
nents of the tumor-associated host response and accelerates
adenocarcinogenesis. Previous studies indicated that PF4 in
steady state suppresses megakaryopoiesis (Lambert et al.,
2007; Oda et al., 2003) and induces hematopoietic stem cell
quiescence (Bruns et al., 2014; Zhao et al., 2014) but can pro-
mote hematopoiesis and megakaryopoiesis under stress condi-
tions, such as radiotherapy or chemotherapy (Aidoudi et al.,
1996; Bruns et al., 2014; Caen et al., 1999). Here, in the context
of cancer, we found a causal link between increased endoge-
nous PF4 levels and (1) expanded megakaryopoiesis, (2) plateletaccumulation in cancer-developing lungs, and (3) accelerated
tumor growth. That PF4 triggers these phenotypes during
carcinogenesis accords with our understanding that cancer
puts chronic stress on the hematopoietic system (Shalapour
and Karin, 2015).
PF4-induced platelet accumulation in tumors is important
because platelets can modulate tumor cells and the tumor
microenvironment to accelerate cancer outgrowth. For example,
platelets can promote tumor angiogenesis (Ho-Tin-Noe´ et al.,
2008; Kuznetsov et al., 2012; Qi et al., 2015; Gebremeskel
et al., 2015; Mezouar et al., 2015), prevent tumor cell recognition
by natural killer cells (Nieswandt et al., 1999; Palumbo et al.,
2005; Placke et al., 2012), and foster metastasis by recruiting
myeloid cells into metastatic niches (Gay and Felding-Haber-
mann, 2011; Labelle et al., 2014). Here we provide evidence for
a direct role of PF4 in platelet accumulation in lung tumors,
both in mouse models and patients.Cell Reports 17, 1764–1772, November 8, 2016 1769
Figure 4. Platelets and Systemic PF4 Production Promote Cancer Progression
(A) Lung weight of PBS-treated and clopidogrel-treated tumor-bearing mice 5 weeks after KP1.9 lung tumor cell injection is shown.
(B) Histochemistry-based quantification of total tumor areas (as percentage of total lung section areas) in PBS- and clopidogrel-treated KP1.9 tumor bearingmice
is shown.
(C) Representative H&E images show lung sections from the same mice as in (B).
(D) Lung weight of Ctrl-LV- and PF4-LV-treated K mice 17 weeks after tumor initiation. Data are shown as the percentage of Ctrl-LV lung weight.
(E) Representative H&E images show lung sections from the same mice as in (A). Asterisks, blood vessels; arrows, normal epithelia; triangles, hyperplasia;
symbols, adenoma. Scale bars represent 100 mm.
(F and G) Histochemistry-based quantifications of total tumor areas (as percentage of total lung section areas) (E) and lung tumor foci (F) in Ctrl-LV- and PF4-LV-
treated K mice are shown.
Results are expressed as mean ± SEM (*p < 0.05 and **p < 0.01). Abbreviations are as follows: Clopid, clopidogrel; Ctrl, control; K, KrasG12D; LV, lentivector. See
also Figure S4.PF4 analogs or fragments can be anti-angiogenic and by
extension exert antitumor activities (Giussani et al., 2003;
Maione et al., 1991; Tanaka et al., 1997). However, increased
circulating native PF4 levels are associated with human lung
cancer (Taguchi et al., 2011; Engels et al., 2015). Importantly,
in this study we used a Pf4 expression cassette that produced
native PF4 in vivo. With this approach, we not only confirmed a
positive association between native Pf4 overexpression and
faster tumor progression but also identified PF4 as a causal fac-
tor driving this phenotype.
Systemically increased PF4 production during de novo carci-
nogenesis selectively amplified medullary megakaryopoiesis
and platelet accumulation at the tumor site. These findings indi-
cate a specific control that is operated by tumors on the host and
that extends beyond the local tumor microenvironment. KP
tumors overexpress several factors, including Pf4 (as per this
study) and Agt (Cortez-Retamozo et al., 2013), yet PF4’s effects
on medullary megakaryopoiesis were distinct from those of AGT
(the Angiotensin II precursor) on extramedullary monocytopoie-1770 Cell Reports 17, 1764–1772, November 8, 2016sis. Consequently, we propose that lung tumors can remotely
control distinct hematopoietic cells by producing different
endocrine factors. These factors (PF4, Angiotensin II, and likely
others) shape the tumor microenvironment, consequently alter
tumor progression, andmay thus be promisingmolecular targets
for anticancer therapy.EXPERIMENTAL PROCEDURES
Mice
KrasLSLG12D/+;p53fl/fl (referred to as KP) and KrasLSLG12D/+ (referred to as K)
mice in a 129/j background were used as conditional mouse models of lung
adenocarcinoma,asdescribedpreviously (Cortez-Retamozoetal., 2012).All an-
imal experiments were approved by the Massachusetts General Hospital Sub-
committee on Research Animal Care. Methods to induce lung adenocarcinoma
in these mice are described in the Supplemental Experimental Procedures.
Human Tumor Samples
Sections from paraffin-embedded lung resection biopsies (n = 29) from
NSCLC patients with known KRAS and TP53 gene mutation status were
obtained from the Department of Pathology at Massachusetts General Hospi-
tal. CD42b immunohistochemistry was performed and evaluated blindly as
described in the Supplemental Experimental Procedures.
PF4 LVs
Concentrated VSV.G-pseudotyped, third-generation LV stocks were produced
and titered as described previously (De Palma and Naldini, 2002). LV copy per
genome (CpG) of samples was calculated using genomic DNA standard curve
with known CpG. The CpG of genomic DNA standard curves and samples
was determined using custom TaqMan assays specific for LVs (Applied Bio-
systems). LVs were injected i.v. 23 104 ng p24/mouse in 50–200 ml, depending
on the infectivity.
Bioinformatics and Statistics
In silico analyses were performed in R. The initial list of murine candidates
used to probe the lung cancer patient microarray dataset was sequentially
transformed from a list of murine proteins into the following: (1) their human
orthologs, (2) their gene symbols, and (3) the corresponding microarray
probe identifications. The list of microarray probes was matched with hu-
man datasets for survival analysis, which used the log-rank test. GraphPad
Prism 6 was used for all statistical analyses. Statistical tests for multi-
variate analyses were performed using two-way ANOVA followed by
Holm-Sidak multiple comparison test. The p values were considered signif-
icant at <0.05.
Gene and Protein Nomenclature
Capitalization of gene and protein symbols is styled according to species (hu-
man gene symbol, PF4; protein symbol, PF4; mouse gene symbol, Pf4; protein
symbol, PF4).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.10.031.
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